GCG and Crohn disease: Gut hormone activity may be coupled with intestinal immune processes, as proinflammatory prostaglandins (PGs) acting via EP4 receptors enhance the release of GLP-1, GLP-2, and PYY (38), and enteroendocrine cell activity is increased in Crohn’s disease affecting the small bowel (39).